These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 19718055)
1. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bacigalupo A; Soraru M; Dominietto A; Pozzi S; Geroldi S; Van Lint MT; Ibatici A; Raiola AM; Frassoni F; De Stefano F; Verdiani S; Casarino L; Barosi G Bone Marrow Transplant; 2010 Mar; 45(3):458-63. PubMed ID: 19718055 [TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A; Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030 [TBL] [Abstract][Full Text] [Related]
3. Survival in young patients with intermediate- / high-risk myelofibrosis: estimates derived from databases for non transplant patients. Siragusa S; Passamonti F; Cervantes F; Tefferi A Am J Hematol; 2009 Mar; 84(3):140-3. PubMed ID: 19123461 [TBL] [Abstract][Full Text] [Related]
4. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906 [TBL] [Abstract][Full Text] [Related]
5. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC. Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807 [TBL] [Abstract][Full Text] [Related]
6. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005]. Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910 [TBL] [Abstract][Full Text] [Related]
7. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. Tefferi A; Siragusa S; Hussein K; Schwager SM; Hanson CA; Pardanani A; Cervantes F; Passamonti F Am J Hematol; 2010 Jan; 85(1):14-7. PubMed ID: 20029953 [TBL] [Abstract][Full Text] [Related]
8. Related donor marrow transplant for chronic myeloid leukemia: patient characteristics predictive of outcome. Enright H; Daniels K; Arthur DC; Dusenbery KE; Kersey JH; Kim T; Miller WJ; Ramsay NK; Vercellotti GM; Weisdorf DJ; McGlave PB Bone Marrow Transplant; 1996 Apr; 17(4):537-42. PubMed ID: 8722351 [TBL] [Abstract][Full Text] [Related]
9. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Dingli D; Schwager SM; Mesa RA; Li CY; Tefferi A Cancer; 2006 Feb; 106(3):623-30. PubMed ID: 16369987 [TBL] [Abstract][Full Text] [Related]
10. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465 [TBL] [Abstract][Full Text] [Related]
11. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Robin M; Tabrizi R; Mohty M; Furst S; Michallet M; Bay JO; Cahn JY; De Coninck E; Dhedin N; Bernard M; Rio B; Buzyn A; Huynh A; Bilger K; Bordigoni P; Contentin N; Porcher R; Socié G; Milpied N Br J Haematol; 2011 Feb; 152(3):331-9. PubMed ID: 21133885 [TBL] [Abstract][Full Text] [Related]
12. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Ciurea SO; Sadegi B; Wilbur A; Alagiozian-Angelova V; Gaitonde S; Dobogai LC; Akard LP; Hoffman R; Rondelli D Br J Haematol; 2008 Apr; 141(1):80-3. PubMed ID: 18324970 [TBL] [Abstract][Full Text] [Related]
13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
15. Conventional hematopoietic stem cell transplants from identical or alternative donors are feasible in recipients relapsing after an autograft. di Grazia C; Raiola AM; Van Lint MT; Lamparelli T; Gualandi F; Berisso G; Bregante S; Dominietto A; Mordini N; Bruno B; Frassoni F; Bacigalupo A Haematologica; 2001 Jun; 86(6):646-51. PubMed ID: 11418375 [TBL] [Abstract][Full Text] [Related]
16. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy. Leitch HA; Chase JM; Goodman TA; Ezzat H; Rollins MD; Wong DH; Badawi M; Leger CS; Ramadan KM; Barnett MJ; Foltz LM; Vickars LM Hematol Oncol; 2010 Mar; 28(1):40-8. PubMed ID: 19557769 [TBL] [Abstract][Full Text] [Related]
17. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940 [TBL] [Abstract][Full Text] [Related]
18. Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation. Belkacémi Y; Labopin M; Hennequin C; Hoffstetter S; Mungai R; Wygoda M; Lundell M; Finke J; Aktinson C; Lorchel F; Durdux C; Basara N Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):544-51. PubMed ID: 17141976 [TBL] [Abstract][Full Text] [Related]
19. A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, gamma glutamyl transferase, donor type and cell dose. Sormani MP; Oneto R; Bruno B; Fiorone M; Lamparelli T; Gualandi F; Raiola AM; Dominietto A; Van Lint MT; Frassoni F; Bruzzi P; Bacigalupo A Bone Marrow Transplant; 2003 Jul; 32(2):205-11. PubMed ID: 12838286 [TBL] [Abstract][Full Text] [Related]